Dataset ID: 9

Back to List

Dataset Details

Study Design
Study Design Background
Evaluation of new MRI-CEST contrast agent based on glucose
Study Description
GLINT glucose-3OMG comparison
Study Type
Preclinical
Study Subtype
In vivo
Publication
Paper Linked
Yes
Paper Title
In vitro and in vivo comparison of MRI chemical exchange saturation transfer (CEST) properties between native glucose and 3-O-Methyl-D-glucose in a murine tumor model
Paper Authors
Anemone A, Capozza M, Arena F, Zullino S, Bardini P, Terreno E, Longo DL, Aime S.
Affiliation
Molecular Imaging Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Center for Preclinical Imaging, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR), Torino, Italy.
Paper Journal
NMR Biomed
Paper Year
2021
Paper DOI
Open Access
Yes
Study Component
Multi Modality Images
No
Imaging Modality
Imaging Sub Modality
Radiation
No
Imaging Coverage
Body
Imaging Target
Glucose transporter (GLUT)
Dataset Information
Institution
IBB-CNR
PI
Dario Longo
Country Of Institution
Italy
Euro Bio Imaging Node
MMMI
Country Of Imaging Facility
Italy
Link To Dataset
Contact Person
In Vivo Experimental Parameters
Number Of Groups
4
Types Of Groups
Glucose injected low dose, glucose injected high dose, 3OMG injected low dose, 3OMG injected high dose
Overall Sample Size
20
Disease Model
Cancer
Organ Or Tissue
Melanoma
Sample Size For Each Group
5, 5, 5, 5
Randomization
No
Blinding
No
Outcome Measures
CEST contrast, tumor volume
Statistical Methods
Unpaired Student's t-test
Species
Strain
C57 BL6
Immune Status
Immunocompetent
Sex
Male
Age
8 weeks
Age At Start Experiment
8 weeks
Weight
25 g
Source Of Animals
Charles River Laboratories, Calco, Italy
Experimental Procedures
Pharmacological Procedures Intervention And Control
No
Blood Sampling
No
Surgical Procedures Including Sham Surgery
No
Pathogen Infection Intervention And Control
No
Analgesic Plan To Relieve Pain Suffering And Distress
No
Anesthesia Type
Gas
Duration
45
Anesthesia Drugs
Isofluran
Anesthesia Dose
1-2%
Monitoring Regime
Respiratoy rate
Euthanasia
Yes
Method
Cervical dislocation
Histology
No
Frequency Of Imaging
Single scan
Overall Scan Length
45
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule
Yes
Contrast Agent Commercial Drug
Glucose, 3OMG
Contrast Agent Chemical Drug
Glucose, 3OMG
Contrast Agent Dose
1.5 g kg, 3.0 g kg
Injection Volume
0,2
Injection Time
20 seconds
Vehicle
Saline
Route Of Administration
Intravenous
Cell Line
B16-F10
Provenance
Collaborator
Cell Injection Route
Subcutaneous
Number Of Cells
500000
Housing Room
Not SPF
Dietary Intervention
No
Food Intake Measured
No
Image Acquisition
Instrument Vendor
Bruker
Instrument Type
Pharmascan 70 16, Biospec
Instrument Specifics
7T, 3T
Correction
No
Raw Data
Yes
QA/QC
No
Image Data
Image Type
Primary image processed images
Format Compression
Raw; DICOM
Dimensions
2D + time
Field Of View
30x30x2 mm
Dimension Extents
64x64x1
Size Description
30x30x2 mm
PI xel Voxel Size Description
0.468x0.468x2 mm
Image Processing Methods
Default reconstruction
Quality Control
No
Image Registration Algorithm
No
Ai Enhanced Algorithm
Yes
QC Info
R2 calculation on raw data, CEST contrast
Analyzed Data
Analysis Result Type
Numerical
Data Used For Analysis
CEST contrast
Analysis Method And Details
Manual delineation of tumor regions
Status
Complete
Updated Year
2022